Single-tablet pioglitazone combination filed in Japan
This article was originally published in Scrip
Takedahas filed an approval submission in Japan for a single-tablet combination of pioglitazone and metformin. The product stands to become the first fixed dose combination for type 2 diabetes in Japan, where pioglitazone, a thiazolidinedione, is already marketed alone as Actos. The single-tablet combination was approved as Actoplus met in the US this August and approved in the EU (as Competact) in July 2007. Japanese filings for Actos as concomitant therapy with either metformin or insulin were made in January and June respectively last year.
You may also be interested in...
Merck/Eisai face US speed bump for combo in first-line liver cancer after FDA decision and although their Phase III trial is already enrolled, completion is not due until 2022, giving time for new competitor to make its mark.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
US pharma giant joins Singapore alliance aiming to encourage regional startups and innovation, in multiple tech-related areas including digital health, through the provision of expertise and support.